Patents Assigned to MedImmune, LLC
  • Publication number: 20160096891
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 7, 2016
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: LIEPING CHEN, SHENG YAO, LINDA LIU, SOLOMON LANGERMANN
  • Patent number: 9272032
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: March 1, 2016
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Publication number: 20160039883
    Abstract: The present disclosure generally relates to immunogens for eliciting an antibody response against respiratory syncytial virus (RSV). More specifically, the present disclosure relates to virus-like particles (VLPs) including a RSV F protein epitope, as well as methods of use thereof. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and young children (Hall et al., NEJM, 360:5888-598, 2009; and Nair et al., Lancet, 375:1545-1555, 2010) and a vaccine to protect this young population is of high priority.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Applicants: MEDIMMUNE, LLC, VLP BIOTECH, INC.
    Inventors: David R. MILICH, David C. WHITACRE, Jeanne H. SCHICKLI
  • Patent number: 9255253
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. In addition, the present invention includes an improved method of rescue, wherein animal cells (e.g., SF Vero cells) are electroporated with plasmids and vectors of the invention.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 9, 2016
    Assignee: MedImmune, LLC
    Inventors: George Kemble, Gregory Duke
  • Publication number: 20160024205
    Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Applicant: MEDIMMUNE, LLC
    Inventors: Brandon Higgs, Wei Zhu, Chris Morehouse, Barbara White, Bahija Jallal, Yihong Yao
  • Patent number: 9238825
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 19, 2016
    Assignee: MedImmune, LLC
    Inventors: Erich Hoffmann, Hong Jin, George Kemble, Zhongying Chen
  • Patent number: 9220775
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 29, 2015
    Assignee: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 9212231
    Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: December 15, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
  • Patent number: 9205148
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: December 8, 2015
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Shannon Marshall, Sheng Yao
  • Patent number: 9206255
    Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: December 8, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Ian Foltz, David Jenkins, Vahe Bedian
  • Publication number: 20150337040
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 26, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Alan HUNTER, Thomas LINKE, Timothy PABST, Michaela WENDELER, Xiangyang WANG, Christopher THOMPSON, Guoling XI, Andrew FULTON
  • Patent number: 9193789
    Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Anthony Coyle, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
  • Patent number: 9181345
    Abstract: The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 10, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Jonathan Zmuda, Christina Strange, Wendy Irene White
  • Patent number: 9176129
    Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: November 3, 2015
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko
  • Publication number: 20150291657
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Application
    Filed: April 10, 2015
    Publication date: October 15, 2015
    Applicant: MEDIMMUNE LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Publication number: 20150291685
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: November 6, 2013
    Publication date: October 15, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Patent number: 9159537
    Abstract: Described herein is a method and system for on-line coupling of capillary isoelectric focusing (cIEF) to high-resolution mass spectrometry in which a sheath flow buffer comprising polar organic solvent and organic acid is used as both an immobilization solution for (cIEF) and an ionization solution for electrospray ionization (ESI).
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: October 13, 2015
    Assignees: University of Notre Dame du Lac, Medimmune, LLC
    Inventors: James McGivney, Guijie Zhu, Norman Dovichi
  • Patent number: 9150927
    Abstract: Without limitation, this disclosure relates to compositions and methods for detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin receptor isoform B (IR-B) in a tissue sample. The disclosure also relates to methods of diagnosis and classification based at least in part upon detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin B (IR-B) in a tissue sample. Methods of treating a subject based upon such a classification are among additional aspects of the disclosure presented herein.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: October 6, 2015
    Assignee: MedImmune, LLC
    Inventors: Jiaqi Huang, Chris Morehouse, Yihong Yao, Theresa Lavalle
  • Patent number: 9120875
    Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 1, 2015
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
  • Patent number: 9119812
    Abstract: Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: September 1, 2015
    Assignee: MedImmune, LLC
    Inventors: Hong Jin, Xing Cheng, Kanta Subbarao